In Q2 CY2026, Phibro Animal Health (NASDAQ:PAHC) missed revenue expectations with flat sales of $378.7 million and an adjusted EPS of $0.57, 13.2% below analyst estimates. The company’s operating margin improved to 10.1%, up from 8.9% the previous year. Despite the quarter’s challenges, Phibro Animal Health has shown decent annualized revenue growth of 10.9% over the last five years, slightly above the industry average. The company’s EPS grew at a remarkable 14.2% compounded annual growth rate over the same period. Wall Street expects Phibro Animal Health’s full-year EPS to grow by 17.4% over the next 12 months.

Read more at Stockstory.org does not belong to a specific media company.: Phibro Animal Health (NASDAQ:PAHC) Misses Q2 CY2026 Revenue Estimates, But Stock Soars 5.5%